Also known as bpc-157 + tb-500, bpc-157 + thymosin β4, bpc-157 / tb4 blend, bpc-157 / tb500, bpc/tb blend
Wolverine is an unregulated research-chemical blend that combines two of the most popular regenerative peptides in the longevity and athletic-recovery community: BPC-157 (a synthetic pentadecapeptide derived from a sequence found in human gastric juice) and TB-500 (a synthetic fragment closely related to thymosin beta-4). The blend is positioned by compounders as a "soft-tissue rescue" formula intended to combine BPC-157's tendon, ligament, and gastrointestinal repair signaling with TB-500's broader cell-migration and angiogenic effects. No human pharmacology, efficacy, or safety data exist for the specific combination product; all available evidence comes from rodent and in-vitro work on the individual components, with the bulk of human reports being uncontrolled anecdote. The peptide is sold "for research use only" and is not approved by any regulatory authority for human therapeutic use.
—
best
price
—
per
mg
—
vendors
tracked
Research-only
stage
Formulation caution
BPC-157 + TB-500 (most common vendor formulation). Some vendors substitute the synthetic 17-mer TB-500 with the full Thymosin Beta-4 protein.
What's in this blend
Recovery
BPC-157 (Body Protection Compound-157, also designated PL 14736 in the Pliva clinical program) is a synthetic 15-amino-acid pentadecapeptide originally derived from a putative cytoprotective fragment of human gastric juice protein.
Recovery
TB-500 is the research-chemical label most commonly applied to a synthetic peptide associated with the actin-binding region of thymosin beta-4 (Tbeta4).
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
Wolverine has no mechanistic literature of its own; mechanism is inferred from the two components. BPC-157 (the synthetic pentadecapeptide PL-14736) has been shown in rodent and cell models to upregulate VEGFR2 expression and activate the Akt/eNOS axis, promoting nitric-oxide-mediated angiogenesis, fibroblast proliferation, collagen organization, and growth-hormone-receptor expression in tendon fibroblasts, with parallel evidence of accelerated healing in transected tendon, ligament, muscle, and gastrointestinal-mucosa models (Sikiric et al.
Pharmacokinetic properties
Half-life
BPC-157 plasma t1/2 ~ minutes to a few hours in rodents (no human PK published); TB-4/TB-500 plasma t1/2 ~2-3 h in animal studies; tissue residence presumed longer than plasma.
Routes
subcutaneous · intramuscular
Bioavailability
Both components are injectable. Oral BPC-157 has been studied in rodents with claims of stability to gastric acid, but human PK is undocumented; TB-500 is not orally bioavailable. No PK or stability data exist for the blended product.
Amino-acid sequence
BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 aa, free acid). TB-500: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Lys (synthetic TB-4 N-terminal 17-23 active-site fragment marketed under the label TB-500; vendor purity and exact sequence vary).
Use & research dosing
Research framing only. Self-experimentation protocols circulating in the peptide community typically pair BPC-157 at 250-500 mcg subcutaneously once or twice daily with TB-500 at 2-5 mg subcutaneously once weekly during a 4-6 week "loading" phase, followed by a 2 mg weekly "maintenance" dose for several additional weeks. No human dose-finding study has been performed for either component, and the rodent doses on which these protocols are loosely based do not translate cleanly to human BSA-adjusted equivalents. Vendors label vials in mg of total peptide content; the ratio between BPC-157 and TB-500 in "Wolverine" products varies by compounder and is rarely independently verified.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Wolverine is sold as a "foundational" healing stack rather than a clinically validated therapy. As of May 2026 there are no human trials, no published PK, and no published safety data for the combination. All human use is off-label, unsupervised, and supplied by research-chemical vendors. The TB-500 component is particularly poorly characterized: most vendor products are believed to be the 17-23 active-site fragment but several analytical surveys have found vials containing full-length TB-4 or unrelated peptides. Buyers relying on this blend for soft-tissue injury should be aware that the supportive evidence is almost entirely preclinical rodent work on the components individually.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
low
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.